Ernest Smith
Chief Executive Officer Immunotolerx Inc.
Seminars
Wednesday 4th March 2026
A Phosphatidylserine-Inspired Lipid Nanoparticle (LNP) Platform for Antigen-Specific Immune Tolerance
2:30 pm
- The Immunotolerex platform employs phosphatidylserine (PS)-containing lipid nanoparticles to re-educate the immune system and induce antigen-specific immune tolerance
- This approach harnesses the endogenous apoptotic cell clearance mechanism, in which PS-bearing nanoparticles engage PS receptors on macrophages and dendritic cells, biasing antigen presentation toward regulatory T-cell induction and suppression of pathogenic immune responses •
- The platform has been validated across multiple in vitro and in vivo studies and is supported by more than 25 peer-reviewed publications
